Clinical Observation Of Amibarigeqi-11 In The Treatment Of Anxiety With Coronary Heart Disease After Percutaneous Coronary Intervention

Objective: To observe the effect of Mongolia medicine Amibrigeqi-11 in the treatment of anxiety with coronary heart disease after PCI,provide reference for clinical treatment and improve the quality of life of the patients.Method: 60 cases with anxiety after PCI were randomly divided into treatment and control group,On the basis of conventional treatment,the patients of treatment group also applied the Mongolian Medicine Amibarigeqi-11,and the control group received Deanxit observing whether clinical symptoms are improved.Before and after treatment were given HAMA?GAD-7 score.In addition,we needed to evaluate the safety and reliability of the treatment.Result: 1.The total effective rate of the treatment group was 93.3 %,higher than that of the control group 87.5%,with statistical difference(P <0.05).2.After treatment,the HAMA?GAD-7 score were lower than before,and the score difference was statistically significant before and after treatment(P <0.05).After treatment,The compare of treatment group?control group in the HAMA?GAD-7 score showed no statistical difference(P >0.05).3.After treatment,the improvement of digestive tract symptoms of the treatment group was significantly better than that of the control group,with statistical significance(p<0.05).4.After treatment,two groups of patients had no obvious adverse reactions and toxic side effects were observed in the treatment.Conclusion: 1.Amibarigeqi-11 can improve the clinical symptoms and quality of life of patients with anxiety after PCI,and there is no obvious toxic side effect,have good clinical application value.2.Amibarigeqi-11 in the effective of digestive tract symptoms with anxiety after PCI were better than Deanxit.